Kymriah genetically modified autologous T cells for infusion Images
Generic Name: tisagenlecleucel
This medication has been identified as Kymriah genetically modified autologous T cells for infusion. It is supplied by Novartis Pharmaceuticals Corporation.
Kymriah is used in the treatment of Acute Lymphoblastic Leukemia; B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma and belongs to the drug class miscellaneous antineoplastics. Kymriah genetically modified autologous T cells for infusion is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Kymriah
- Generic Name
- tisagenlecleucel
- Strength
- genetically modified autologous T cells for infusion
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Novartis Pharmaceuticals Corporation
- National Drug Code (NDC)
- 00078-0846
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi (tafasitamab-cxix) is used for the treatment of relapsed or refractory diffuse large B-cell ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma, two types of non-Hodgkin ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Lunsumio
Lunsumio (mosunetuzumab-axgb) is used for the treatment of relapsed or refractory follicular ...
Columvi
Columvi is used to treat certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell ...
More about Kymriah (tisagenlecleucel)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.